Levothyroxine Drug Interactions: Complete FDA-Data Guide to Major & Moderate Risks

Levothyroxine is one of the most commonly prescribed medications in the United States — approximately 20 million prescriptions are filled annually. Yet despite its ubiquity, it remains one of the drugs most vulnerable to significant drug interactions that can render it ineffective. The FDA's drug labeling database reveals 10 major and moderate interaction pathways involving levothyroxine, many of which go unnoticed by patients and caregivers until thyroid function tests reveal rising TSH levels or clinical hypothyroid symptoms emerge.

Understanding these interactions is critical: even moderate reductions in levothyroxine bioavailability can require dose adjustments of 25–50%, and the consequences of unmanaged interactions include fatigue, weight gain, depression, and cardiovascular complications in patients who depend on consistent thyroid hormone replacement.

What Is Levothyroxine and Why Is It Prescribed?

Levothyroxine is a synthetic form of thyroxine (T4), the primary hormone produced by the thyroid gland. It is prescribed to treat hypothyroidism — a condition affecting roughly 4.6% of the U.S. population — and is also used to suppress TSH in thyroid cancer patients and to manage goiter. The drug works by replacing or supplementing insufficient natural thyroid hormone production, restoring metabolic function and energy production.

Because levothyroxine has a narrow therapeutic window, even modest changes in absorption or metabolism can push patients out of their therapeutic range, making drug interaction vigilance essential.

Major Interactions: Absorption-Reducing Agents

The FDA labels six interactions as major severity, the most serious category. The majority stem from one mechanism: reduced gastrointestinal absorption.

Colesevelam (Welchol) — 40% Absorption Reduction

Colesevelam is a bile acid sequestrant used to lower cholesterol. According to FDA drug labeling data, in vivo studies demonstrated that colesevelam significantly decreases levothyroxine exposure. Postmarketing reports have documented elevated TSH in patients taking thyroid hormone replacement concurrently with colesevelam — the hallmark sign that levothyroxine levels have dropped below therapeutic levels.

The mechanism is straightforward: colesevelam binds levothyroxine in the gastrointestinal tract, preventing absorption. Patients on both drugs require careful TSH monitoring and likely need dose separation or dose escalation of levothyroxine.

Lanthanum Carbonate (Fosrenol) — 40% Bioavailability Loss

Lanthanum carbonate is a phosphate binder used in chronic kidney disease. FDA labeling explicitly states that lanthanum carbonate decreases levothyroxine bioavailability by approximately 40%. The interaction is mediated by lanthanum's cationic charge, which binds the anionic levothyroxine molecule in the intestinal lumen.

The FDA recommendation is clear: administer levothyroxine at least 2 hours before or after lanthanum carbonate, and monitor TSH closely. For patients requiring both medications, this separation is non-negotiable.

Orlistat (Xenical, Alli) — Hypothyroidism Reported

Orlistat is an over-the-counter weight loss medication that reduces dietary fat absorption. FDA labeling documents hypothyroidism reported in patients taking orlistat concurrently with levothyroxine. The mechanism is reduced absorption of the lipophilic levothyroxine molecule in the presence of decreased fat absorption.

The FDA recommends administering levothyroxine at least 4 hours apart from orlistat — the longest separation interval of any levothyroxine interaction. This reflects the severity and unpredictability of the interaction.

Epinephrine — Potentiation Risk (Major)

Unlike the absorption-reducing interactions above, epinephrine presents a different major risk: potentiation. FDA labeling states that levothyroxine may potentiate the effects of epinephrine. In patients with coronary artery disease or arrhythmias, this potentiation can increase the risk of chest pain, palpitations, or arrhythmias — particularly during emergency use of epinephrine auto-injectors (EpiPens).

This interaction is not dose-dependent in the traditional sense; rather, it reflects levothyroxine's role in upregulating tissue sensitivity to catecholamines.

Moderate Interactions: Bile Acid Sequestrants and Ion-Binding Agents

Four additional interactions carry moderate severity rating — a level that still warrants active management but may not require immediate dose adjustment if recognized and monitored.

Cholestyramine (Questran) — Delayed/Reduced Absorption

Cholestyramine, like colesevelam, is a bile acid sequestrant. FDA labeling documents that cholestyramine may delay or reduce thyroxine absorption. The effect is similar to colesevelam but often slightly less severe. Nonetheless, the same principle applies: separate dosing by several hours and monitor TSH.

Sodium Polystyrene Sulfonate (Kayexalate) — Binding Interaction

Sodium polystyrene sulfonate is a cation-exchange resin used to treat hyperkalemia. FDA labeling warns that it may bind thyroxine and decrease gastrointestinal absorption. The FDA specifically recommends administering levothyroxine at least 3 hours before or after sodium polystyrene sulfonate.

This is a drug often given acutely in hospital settings; coordination between pharmacy and prescribers is essential to prevent inadvertent concurrent dosing.

Sevelamer Carbonate (Renvela) — Bioavailability Reduction

Sevelamer carbonate is a phosphate binder for kidney disease patients — a population that may already have thyroid dysfunction. FDA labeling states that sevelamer carbonate may reduce levothyroxine bioavailability with clinically significant effects on efficacy. The interaction mechanism mirrors lanthanum carbonate: ionic binding in the intestine.

The FDA recommends considering separation of administration timing, though the specific interval is left to clinical judgment. Most practitioners use the 2–4 hour separation model established for other binders.

Albuterol Sulfate (Moderate) — Potentiation of Adrenergic Effects

FDA labeling notes that levothyroxine potentiates the effects of albuterol sulfate, a beta-2 agonist bronchodilator. While not as dramatic as the epinephrine interaction, patients taking both drugs may experience increased tremor, palpitations, or nervousness, particularly at higher albuterol doses or during acute asthma exacerbations.

How to Safely Manage Levothyroxine Interactions

• Separate dosing by 4–6 hours minimum: Levothyroxine should be taken on an empty stomach, at least 30 minutes before breakfast. Any drug known to reduce absorption (bile acid sequestrants, phosphate binders, orlistat) should be dosed separately, ideally hours apart. Track the timing in a pill organizer or medication app.
• Inform all prescribers: Because levothyroxine is so common, new prescribers may not ask about it. Proactively declare all thyroid medications when starting any new drug.
• Monitor TSH regularly: If you begin or stop a medication that interacts with levothyroxine, request a TSH recheck 6–8 weeks later. Dose adjustments should be made only after TSH has stabilized at the new level.
• Watch for symptom changes: Fatigue, weight gain, cold intolerance, or depression may signal rising TSH. Report these to your prescriber even if TSH labs are pending.
• Avoid absorption-reducing foods and supplements: Iron, calcium, and certain fiber supplements also reduce levothyroxine absorption. Maintain consistent timing with levothyroxine dosing.

The Bottom Line: Data-Driven Safety

Levothyroxine interacts significantly with at least 10 commonly prescribed medications. Six of these are classified as major interactions by the FDA, and all require either dose separation, TSH monitoring, or clinical vigilance. The good news: these interactions are entirely manageable with awareness and coordination between patient, pharmacy, and prescriber.

Patients on levothyroxine who start cholesterol-lowering drugs, weight loss medications, or phosphate binders should expect a proactive conversation about timing and monitoring. If that conversation doesn't happen, ask — your pharmacist is the expert resource here.

Check Your Full Medication Profile Today

Levothyroxine is just one drug; most patients take multiple medications that may interact in unseen ways. The safest approach is a comprehensive cross-check of your entire medication list.

Visit checkdruginteractions.com — the most comprehensive drug interaction checker on the internet. Our database contains over 250,000 FDA-labeled drug records, updated monthly from openFDA and the National Library of Medicine. Enter up to 20 drugs simultaneously and receive instant severity-ranked interaction alerts, separation recommendations, and monitoring guidance — all sourced directly from FDA labeling data. No account required. Get your personalized interaction report in seconds.